COGT250117C12500
- 0.10
- 0.000.00%
Cogent Biosciences Newsroom
This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year
Cogent Biosciences' Cole Pinnow Acquires 2,085% More Stock
Cogent and ModivCare Gain After Insider Purchases
Cogent Biosciences Insider Bought Shares Worth $332,413, According to a Recent SEC Filing
Cogent Biosciences Price Target Cut to $14.00/Share From $17.00 by HC Wainwright & Co.
Cogent Biosciences Is Maintained at Buy by HC Wainwright & Co.
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $23
Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $14
Buy Rating Maintained for Cogent Biosciences Amid Competitive Pressures and Promising Trial Results
Cogent Biosciences Announces 2025 Milestones, SUMMIT Results In NonAdvSM In July, PEAK Phase 3 In 2nd-Line GIST By Year-End, APEX In AdvSM in H2; Presenting at J.P. Morgan Healthcare Conference Tomorrow At 10:30 AM ET
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
Cogent Biosciences (COGT) Gets a Buy From J.P. Morgan
Express News | Cogent Biosciences Inc : JP Morgan Raises Target Price to $23 From $21
Needham Downgrades Cogent Biosciences to Hold, Maintains Price Target to $15